Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.68M$7.68Mderivedno prior Q4 2023 on file Net Income-$94.17M-$94.17MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$96,365,000N/M Operating Cash Flowderived-$57,388,000N/M Margins · derivedOperating margin-1254.8%
Net margin-1226.2%
ended Dec 31, 2024 · filed Mar 3, 2025 · 62 d after period end